-
Je něco špatně v tomto záznamu ?
The cytotoxic effect of α-tomatine in MCF-7 human adenocarcinoma breast cancer cells depends on its interaction with cholesterol in incubation media and does not involve apoptosis induction
L. Sucha, M. Hroch, M. Rezacova, E. Rudolf, R. Havelek, L. Sispera, J. Cmielova, R. Kohlerova, A. Bezrouk, P. Tomsik,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2006 do Před 1 rokem
ProQuest Central
od 2012-01-01
Health & Medicine (ProQuest)
od 2012-01-01
PubMed
24100733
DOI
10.3892/or.2013.2778
Knihovny.cz E-zdroje
- MeSH
- apoptóza účinky léků MeSH
- buněčný cyklus účinky léků MeSH
- cholesterol metabolismus MeSH
- lidé MeSH
- MFC-7 buňky MeSH
- nádorový supresorový protein p53 metabolismus MeSH
- nádory prsu farmakoterapie metabolismus patologie MeSH
- proliferace buněk účinky léků MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- tomatin aplikace a dávkování analogy a deriváty MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In recent years, α-tomatine has been studied for its anticancer activity. In the present study, we focused on the cytotoxic effect of α-tomatine in the MCF-7 human breast adenocarcinoma cell line, its mechanism of action, biotransformation and stability in the culture medium. We observed an inhibition of cell proliferation and viability at concentrations of 6 and 9 µM but then a recovery of cells occurred. The recovery was not caused by the biotransformation of α-tomatine in MCF-7 cells, but by a substantial decrease in the concentration of α-tomatine in the culture medium due to its binding with cholesterol. Regarding the mechanism of action of α-tomatine, we observed no DNA damage, no changes in the levels of the proteins p53 and p21(WAF1/Cip1), and no apoptosis (neither activated caspase-8 and -9, nor sub-G1 peak, or morphological signs). We found a loss of ATP in α-tomatine-treated cells. These results support the conclusion that α-tomatine does not induce apoptosis in the MCF-7 cell line.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063915
- 003
- CZ-PrNML
- 005
- 20171219082048.0
- 007
- ta
- 008
- 140704s2013 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/or.2013.2778 $2 doi
- 035 __
- $a (PubMed)24100733
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Sucha, Lenka $u Department of Medical Biochemistry, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
- 245 14
- $a The cytotoxic effect of α-tomatine in MCF-7 human adenocarcinoma breast cancer cells depends on its interaction with cholesterol in incubation media and does not involve apoptosis induction / $c L. Sucha, M. Hroch, M. Rezacova, E. Rudolf, R. Havelek, L. Sispera, J. Cmielova, R. Kohlerova, A. Bezrouk, P. Tomsik,
- 520 9_
- $a In recent years, α-tomatine has been studied for its anticancer activity. In the present study, we focused on the cytotoxic effect of α-tomatine in the MCF-7 human breast adenocarcinoma cell line, its mechanism of action, biotransformation and stability in the culture medium. We observed an inhibition of cell proliferation and viability at concentrations of 6 and 9 µM but then a recovery of cells occurred. The recovery was not caused by the biotransformation of α-tomatine in MCF-7 cells, but by a substantial decrease in the concentration of α-tomatine in the culture medium due to its binding with cholesterol. Regarding the mechanism of action of α-tomatine, we observed no DNA damage, no changes in the levels of the proteins p53 and p21(WAF1/Cip1), and no apoptosis (neither activated caspase-8 and -9, nor sub-G1 peak, or morphological signs). We found a loss of ATP in α-tomatine-treated cells. These results support the conclusion that α-tomatine does not induce apoptosis in the MCF-7 cell line.
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cholesterol $x metabolismus $7 D002784
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a tomatin $x aplikace a dávkování $x analogy a deriváty $7 D014053
- 650 _2
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 700 1_
- $a Rezacova, Martina
- 700 1_
- $a Rudolf, Emil
- 700 1_
- $a Havelek, Radim
- 700 1_
- $a Sispera, Ludek
- 700 1_
- $a Cmielova, Jana
- 700 1_
- $a Kohlerova, Renata
- 700 1_
- $a Bezrouk, Ales
- 700 1_
- $a Tomsik, Pavel
- 773 0_
- $w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 30, č. 6 (2013), s. 2593-2602
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24100733 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20171219082244 $b ABA008
- 999 __
- $a ok $b bmc $g 1031399 $s 862647
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 30 $c 6 $d 2593-2602 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
- LZP __
- $a Pubmed-20140704